fbpx

Marksans Pharma Ltd

MARK.NS

$2.94

Closing

▲0.77%

1D

▼-14.24%

YTD

MARK

BBG001S86217

Exchange

Sector

Market cap

$1.33B

Volume

691,212

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$1.33B

Analysts' Rating

STRONG BUY

Price Target (Mean)

3.64

Total Analysts

2

P/E

33.20

Operating Margin

30.38%

Beta

1.38

Revenue Growth

20.84%

52 week high

$4.15

52 week low

$1.50

Div. Yield

0.24%

EPS Growth

0.00

Company Profile

Marksans Pharma Limited is an India-based company, which is engaged in research, manufacturing and marketing of generic pharmaceutical formulations in the global markets. The Company’s product portfolio spreads various therapeutic segments of cardiovascular system (CVS), central nervous system (CNS), antidiabetic, pain management, cough and cold, gastroenterological, and anti-allergies. Its product portfolio includes tablets (plain, enteric-coated and film-coated), hard capsules, soft gelatin capsules, oral liquids and ointments. Its consumer self-care products (over the counter) include pain management, upper respiratory, digestive health, vitamins minerals and supplements (VMS) and skin care products. The Company’s prescription – Rx therapeutic segments include CVS, CNS, oncology, anti-diabetics and anti-biotic. Its end consumers include retail chains, pharmacy stores, hospitals and institutions. It has manufacturing facilities in India, the United Kingdom and the United States.